Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MPI | P34949 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | TOP1 | P11387 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Demannose SCHEMBL9576995 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Demannose SCHEMBL1277 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Demannose SCHEMBL94289 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Demannose SCHEMBL20956808 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Demannose SCHEMBL20500378 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Demannose SCHEMBL12474438 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Demannose SCHEMBL5070598 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Demannose SCHEMBL17144009 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Galactose SCHEMBL20818999 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 | |
| Galactose SCHEMBL8371122 | 1.00 | LMNA (0.58) | LMNAL3MBTL1TDP1PDE4AAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260130404-A1 | SWEETNESS AND TASTE IMPROVEMENT OF NON-SUCROSE SWEETENERS WITH D-SUGARS OR L-SUGARS | THE COCA COLA CO (US) | 2026-05-14 | — | — | US | claimed |
| WO-2024200578-A1 | BIOCATALYTIC PREPARATION OF AN ORGANIC SUBSTANCE COMPRISING A CARBONYL GROUP | CASCAT GMBH (DE) | 2024-10-03 | — | — | WO | claimed |
| CN-117903386-A | Method for realizing liquid phase polymerization of high-concentration polyhydroxy aldehyde or (and) polyhydroxy ketone through liquid thereof under high-temperature condition | 厦门碳控科技投资有限公司 | 2024-04-19 | — | — | CN | claimed |
| US-20240110195-A1 | METHOD FOR TERRESTRIAL CARBON SEQUESTRATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2024-04-04 | — | — | US | claimed |
| CN-115838495-B | Self-supporting covalent cross-linking functional polyelectrolyte porous membrane and preparation method and application thereof | 南开大学 | 2023-09-19 | — | — | CN | claimed |
| WO-2022221541-A9 | METHOD FOR TERRESTRIAL CARBON SEQUESTRATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2023-08-17 | — | — | WO | claimed |
| CN-115838495-A | Self-supporting covalent cross-linking functional polyelectrolyte porous membrane and preparation method and application thereof | 南开大学 | 2023-03-24 | — | — | CN | claimed |
| WO-2022221541-A2 | METHOD FOR TERRESTRIAL CARBON SEQUESTRATION | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2022-10-20 | — | — | WO | claimed |
| US-20220154242-A1 | METHOD FOR MODIFYING SUBSTRATE SPECIFICITY OF GLUCOSE DEHYDROGENASE AND AGENT FOR MODIFYING SUBSTRATE SPECIFICITY OF GLUCOSE DEHYDROGENASE | KIKKOMAN CORPORATION (JP) | 2022-05-19 | — | — | US | claimed |
| EP-3684942-A1 | PROCESS FOR ENZYMATIC OXIDATION OF LINEAR CARBOHYDRATES | Technische Universität München (DE) | 2020-07-29 | — | — | EP | claimed |
| US-4421568-A | Process for making L-sugars and D-fructose | HYDROCARBON RESEARCH, INC. (US) | 1983-12-20 | — | — | US | claimed |
| EP-0002588-B1 | PLEUROMUTILIN GLYCOSIDE DERIVATIVES, FORMULATIONS CONTAINING THEM AND PROCESSES FOR THEIR PREPARATION | ELI LILLY AND COMPANY (US) | 1983-04-06 | — | — | EP | claimed |
| US-4371616-A | Process for producing L-sugars | HYDROCARBON RESEARCH, INC. (US) | 1983-02-01 | — | — | US | claimed |
| US-4262032-A | L-HEXOSE MONOSACCHARIDES | BIOSPHERICS INCORPORATED (US) | 1981-04-14 | — | — | US | claimed |
| US-4228198-A | Sweetening compositions containing arabinogalactan | TATE & LYLE LIMITED (GB) | 1980-10-14 | — | — | US | claimed |
| US-RE30413-E | ANTIBIOTICS; ANTITUMOR AGENTS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1980-10-07 | — | — | US | claimed |
| EP-0002588-A1 | Pleuromutilin glycoside derivatives, formulations containing them and processes for their preparation | ELI LILLY AND COMPANY (US) | 1979-06-27 | — | — | EP | claimed |
| US-4130709-A | BACTERICIDE | ELI LILLY AND COMPANY (US) | 1978-12-19 | — | — | US | claimed |
| US-4122205-A | THAUMATIN OR MONELLIN | TATE & LYLE LTD. (GB) | 1978-10-24 | — | — | US | claimed |
| US-3932374-A | ANTITUMOR AGENTS | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JA) | 1976-01-13 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130404-A1 | SWEETNESS AND TASTE IMPROVEMENT OF NON-SUCROSE SWEETENERS WITH D-SUGARS OR L-SUGARS | TAS2R40, TAS2R13, TAS2R31 | LMNA 4742/4885L3MBTL1 3224/4885TDP1 2545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.